BD is recalling hundreds of thousands of its Alaris infusion pumps and vital sign monitors due to multiple system faults, including software- and user-related issues. According to the FDA, the errors ...

Washington, D.C.--(Newsfile Corp. - December 16, 2024) - The Securities and Exchange Commission today announced settled charges against Becton, Dickinson and Company, a New Jersey-based medical device ...

A new group of recalls for a repair piece installed in some of BD’s Alaris infusion pumps joins more than a dozen others on the long list of serious recalls involving the device in the last decade.

To data, there have been 13 reported injuries. Becton Dickinson (BD)/Carefusion 303 is recalling the Alaris infusion pump due to incompatibility issues with Cardinal Health Monoject syringes. The Food ...

This story was originally published on MedTech Dive. To receive daily news and insights, subscribe to our free daily MedTech Dive newsletter. BD will pay a $175 million civil penalty to settle charges ...

Gift Article 10 Remaining As a subscriber, you have 10 articles to gift each month. Gifting allows recipients to access the article for free. A voluntary safety recall of widely used Alaris infusion ...

Becton, Dickinson and Company’s BDX, or popularly known as BD, initiated the recall of its infusion pumps last month after customer reports indicated software issues, potentially leading to inaccurate ...

Today's clearance further enhances BD leadership in the infusion pump market. The updated BD Alaris™ Infusion System will help empower hospitals and health systems to optimize their workflows and ...

Becton, Dickinson and Company BDX, popularly known as BD, recently received the FDA’s 510(k) clearance for its updated BD Alaris Infusion System. This is expected to enable both remediation and a ...